
    
      Chronic lymphocytic leukemia remains incurable and particularly in ultra-high risk subgroup,
      and the prognosis of these patients is still dismal.

      This is a phase III, multicenter perspective clinical trial of combination of fresh frozen
      plasma(FFP), high dose methylprednisolone(HDMP) and rituximab for ultra-high risk chronic
      lymphocytic leukemiaThe. The main purpose of this study is to investigate efficacy and safety
      of this combinated regimen in subgroup of CLL patients.

      All the enrolled patients will be followed during and after the treatment period up to one
      year. Interim and final evaluation will be done after each cycle of treatment.
    
  